| Psoriasis vulgaris

Bryhali vs Cimzia

Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.

Deep comparison between: Bryhali vs Cimzia with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsCimzia has a higher rate of injection site reactions vs Bryhali based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Cimzia but not Bryhali, including UnitedHealthcare

Category

Bryhali

Cimzia

At A Glance

RouteTopical

FrequencyDaily

ClassTopical corticosteroid

RouteSC injection

FrequencyEvery 2-4 weeks

ClassTNF-alpha inhibitor

Indications

Psoriasis vulgaris

Crohn Disease
Rheumatoid Arthritis
Juvenile polyarthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Non-Radiographic Axial Spondyloarthritis
Psoriasis vulgaris

Dosing

Psoriasis vulgaris Apply a thin layer to affected areas once daily; do not exceed 8 weeks of treatment or approximately 50 g per week; discontinue when control is achieved; avoid occlusive dressings unless directed, and do not use on face, groin, or axillae.

Crohn Disease 400 mg SC (two 200 mg injections) at Weeks 0, 2, and 4; maintenance 400 mg every 4 weeks.

Rheumatoid Arthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.

Juvenile polyarthritis Weight-based SC dosing at Weeks 0, 2, and 4, then maintenance every 2 weeks: 100 mg loading / 50 mg maintenance (10 to <20 kg); 200 mg loading / 100 mg maintenance (20 to <40 kg); 400 mg loading / 200 mg maintenance (>=40 kg).

Arthritis, Psoriatic 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.

Ankylosing spondylitis, Non-Radiographic Axial Spondyloarthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks or 400 mg every 4 weeks.

Psoriasis vulgaris 400 mg SC every 2 weeks; for patients <=90 kg, 400 mg at Weeks 0, 2, and 4 followed by 200 mg every 2 weeks may be considered.

Contraindications

—

History of hypersensitivity reaction to certolizumab pegol or any excipient (including angioedema, anaphylaxis, serum sickness, or urticaria)

Drug Interactions

73View drug interactions

1383View drug interactions

Adverse Reactions

Most common (>=1%) Upper respiratory tract infection, application site dermatitis, hyperglycemia

Most common (>=8%) Upper respiratory infections (18%), rash (9%), urinary tract infections (8%)

Serious Serious infections, malignancies, heart failure, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematologic reactions, autoimmunity, immunosuppression

Postmarketing Systemic vasculitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, new or worsening psoriasis (all subtypes), lichenoid skin reaction, sarcoidosis, melanoma, Merkel cell carcinoma

Pharmacology

Topical corticosteroid; corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation, though the precise mechanism of action in plaque psoriasis is unknown.

Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody that selectively neutralizes soluble and membrane-associated human TNF-alpha, a key pro-inflammatory cytokine; it lacks an Fc region and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Bryhali